Key Takeaways
- Microdosing tirzepatide means using doses below the standard 2.5 mg starting dose, typically 0.5 mg to 1.5 mg per week.
- The standard FDA-approved Mounjaro and Zepbound titration starts at 2.5 mg weekly. Microdosing is an off-label, clinician-directed protocol that's not recognized in product labeling.
- Patients use microdoses for three reasons: severe side effects on standard doses, prevention or maintenance after weight goal is reached, or extreme dose sensitivity.
- The unit math at 10 mg/mL: 0.5 mg = 5 units, 1.0 mg = 10 units, 1.5 mg = 15 units, 2.0 mg = 20 units.
- Clinical trial data on tirzepatide doses below 2.5 mg is limited, so microdose protocols rest on individual provider judgment rather than published randomized data.
Direct answer (40-60 words)
Microdose tirzepatide refers to using doses below the standard 2.5 mg weekly starting dose, typically 0.5 mg to 1.5 mg per week. Patients use microdoses to manage severe side effects, maintain results after reaching a goal weight, or treat very dose-sensitive cases. Microdosing is off-label and not part of the FDA-approved labeling for Mounjaro or Zepbound.
Table of contents
- The 30-second answer
- Standard tirzepatide titration vs microdosing
- Common microdose protocols
- Unit math for every microdose
- Why patients microdose: three real scenarios
- Microdosing for maintenance after goal weight
- What the clinical evidence does and doesn't say
- Side effects on microdoses
- Risks and limitations of microdosing
- FAQ
- Sources
- Footer disclaimers
Standard tirzepatide titration vs microdosing
The FDA-approved label for tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) calls for a stepped titration over several months:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Week | Standard dose |
|---|---|
| 1-4 | 2.5 mg weekly |
| 5-8 | 5 mg weekly |
| 9-12 | 7.5 mg weekly (titration step) |
| 13-16 | 10 mg weekly |
| 17-20 | 12.5 mg weekly |
| 21+ | 15 mg weekly (maximum) |
The 2.5 mg starting dose is itself a titration dose, not a maintenance dose. Per the prescribing information, 2.5 mg is used to allow the body to adjust to the medication, with the expectation that most patients will move up to therapeutic doses (5 mg minimum) within 4 to 8 weeks (Eli Lilly Zepbound prescribing information, 2024).
Microdosing departs from this protocol in one of three ways:
- Starting below 2.5 mg (typically 0.5 mg to 2.0 mg per week)
- Holding at a sub-therapeutic dose longer than the standard 4-week titration
- Tapering down to a microdose for maintenance after reaching a weight goal
Each of these is off-label. The clinician decides whether and how to microdose based on patient-specific factors. There's no FDA guidance, no NCCN-style consensus protocol, and only limited published data on the effects of microdosing.
Common microdose protocols
Three patterns appear most often in clinician-directed microdose use:
Protocol A: Titration starter for high-sensitivity patients
| Week | Dose |
|---|---|
| 1-2 | 0.5 mg |
| 3-4 | 1.0 mg |
| 5-6 | 1.5 mg |
| 7-8 | 2.0 mg |
| 9+ | 2.5 mg (then standard titration above) |
Used when a patient has had severe side effects on prior GLP-1 trials, has a low BMI for tirzepatide therapy, or is highly anxious about side effects. Adds 6 to 8 weeks to the time-to-therapeutic-dose.
Protocol B: Hold at low dose for tolerance
| Phase | Dose |
|---|---|
| Months 1-2 | 2.5 mg (hold) |
| Months 3-4 | 5 mg (hold) |
| Months 5+ | Continue 5 mg or move up if needed |
Not strictly microdosing (it stays at 2.5 mg, the FDA-approved starting dose), but extends the titration timeline beyond the standard 4 weeks. Used when 2.5 mg is producing meaningful weight loss and the patient is hesitant to move up.
Protocol C: Maintenance microdose after weight goal reached
| Phase | Dose |
|---|---|
| Active titration | Standard, up to 7.5 to 15 mg |
| Goal weight reached | Hold at maintenance dose |
| Long-term maintenance | Taper to 1.0 to 2.5 mg weekly |
Used to prevent weight regain after reaching a target. Some patients tolerate a step down without losing the weight-stabilizing effect.
These three patterns aren't formally named or endorsed by Eli Lilly or any guideline body. They're descriptions of what providers do in practice.
Unit math for every microdose
Most compounded tirzepatide is dispensed at 10 mg/mL. At that concentration, the math is simple: every milligram is 10 units on a U-100 insulin syringe, and every dose comes out to a whole-number unit reading.
| Dose | At 10 mg/mL | At 5 mg/mL | At 20 mg/mL |
|---|---|---|---|
| 0.25 mg | 2.5 units (0.025 mL) | 5 units (0.05 mL) | 1.25 units (0.0125 mL) |
| 0.5 mg | 5 units (0.05 mL) | 10 units (0.10 mL) | 2.5 units (0.025 mL) |
| 0.75 mg | 7.5 units (0.075 mL) | 15 units (0.15 mL) | 3.75 units (0.0375 mL) |
| 1.0 mg | 10 units (0.10 mL) | 20 units (0.20 mL) | 5 units (0.05 mL) |
| 1.25 mg | 12.5 units (0.125 mL) | 25 units (0.25 mL) | 6.25 units (0.0625 mL) |
| 1.5 mg | 15 units (0.15 mL) | 30 units (0.30 mL) | 7.5 units (0.075 mL) |
| 1.75 mg | 17.5 units (0.175 mL) | 35 units (0.35 mL) | 8.75 units (0.0875 mL) |
| 2.0 mg | 20 units (0.20 mL) | 40 units (0.40 mL) | 10 units (0.10 mL) |
| 2.25 mg | 22.5 units (0.225 mL) | 45 units (0.45 mL) | 11.25 units (0.1125 mL) |
A few practical notes on the math:
- A 0.3 mL U-100 insulin syringe has half-unit markings, which lets you draw 2.5 units, 7.5 units, or 12.5 units accurately.
- A 1.0 mL U-100 insulin syringe has 1-unit markings; fractional draws below 5 units are hard to read accurately.
- Doses below 2.5 units (e.g., 0.25 mg at 10 mg/mL) are at the limit of what an insulin syringe can measure reliably. Most compounding pharmacies don't dispense for protocols requiring such small draws.
For more on syringe choice and the unit-conversion logic, see our tirzepatide units conversion guide.
Why patients microdose: three real scenarios
Scenario 1: Severe nausea and vomiting on 2.5 mg. A patient starts on 2.5 mg, has persistent nausea for 10 days, vomits twice, and loses 2 kg in week one (much of it dehydration). Continuing the standard protocol risks intolerable adverse events. The provider drops to 1 mg weekly for 4 weeks, then moves to 1.5 mg for 4 weeks, then to 2.5 mg standard. Total titration time: 12 to 16 weeks instead of 4. Patient stays on therapy.
Scenario 2: Lower BMI patient with significant family history. A patient with BMI 28 and strong family history of type 2 diabetes is starting tirzepatide for prevention rather than weight loss alone. The provider chooses a slow microdose start (0.5 mg, then 1 mg, then 1.5 mg) to assess tolerance, with the option to titrate up to 2.5 to 5 mg as a long-term maintenance dose.
Scenario 3: Maintenance after 25% weight loss on 10 mg. A patient lost 25% of starting body weight on tirzepatide 10 mg over 18 months. The provider works toward sustaining the loss without continuing the full active-titration dose. They taper down: 7.5 mg for 3 months, 5 mg for 3 months, 2.5 mg for 3 months, with monthly weight checks. If weight starts to climb, the dose increases. Some patients hold at 2.5 mg or even 1.5 mg as a long-term maintenance dose.
These scenarios represent real clinical decisions made by independent licensed providers. They don't represent FDA-approved protocols and shouldn't be self-prescribed.
Microdosing for maintenance after goal weight
The most common reason patients ask about microdosing is the maintenance question: "I lost the weight; can I just stay on a tiny dose forever?"
The honest answer involves uncertainty. Studies of GLP-1 maintenance therapy after weight loss have largely focused on continued therapeutic dosing, not microdose maintenance. The STEP 4 trial (Rubino et al., JAMA 2021) found that patients on continued 2.4 mg weekly semaglutide maintained their weight loss while patients switched to placebo regained roughly two-thirds of lost weight by week 68. The implication: stopping entirely causes regain. The implication for microdosing as maintenance is less clear because it hasn't been studied head-to-head against either continuing the full dose or stopping.
Some clinical observations support a maintenance microdose:
- Tirzepatide's half-life is roughly 5 days, so weekly dosing maintains steady-state concentration. A lower weekly dose maintains a lower steady-state concentration but still provides some receptor activation.
- The dose-response curve for weight maintenance is flatter than the dose-response curve for active weight loss. Less drug is needed to hold a weight than to actively lose.
- Patient self-reports often show that 1 to 2.5 mg weekly maintains weight in patients who took 7.5 to 15 mg actively. This isn't randomized data, but it's consistent.
Some considerations against:
- Rapid taper-down can trigger weight regain that's difficult to reverse.
- Side effects don't fully disappear at microdoses; some patients report they prefer staying at a slightly higher dose with occasional missed weeks.
- The FDA labeling doesn't endorse maintenance microdosing, so clinicians using it are operating off-label.
Maintenance microdosing decisions belong in a clinician-patient conversation, with monthly weight tracking and the option to titrate up if weight climbs.
What the clinical evidence does and doesn't say
The SURMOUNT-1 trial enrolled patients at 5 mg, 10 mg, and 15 mg weekly tirzepatide doses (Jastreboff et al., NEJM 2022). The 2.5 mg dose appeared in titration but wasn't a maintenance arm. Doses below 2.5 mg weren't studied.
The SURPASS trials (1 through 5) for type 2 diabetes used the same 5/10/15 mg dose levels and 2.5 mg as a starting titration dose only (Frias et al., NEJM 2021).
What this means for microdosing:
- The published efficacy data is on 5 mg, 10 mg, and 15 mg.
- The 2.5 mg dose has efficacy data as a 4-week titration step but limited data as a long-term dose.
- Doses below 2.5 mg have essentially no published randomized efficacy data.
Reasonable extrapolation from pharmacokinetics suggests that 1 to 2 mg weekly tirzepatide produces meaningful receptor activation, and meaningful but smaller weight effects. This is theoretical reasoning, not clinical trial evidence.
A clinician choosing a microdose protocol is making a judgment call based on incomplete evidence. The best microdose protocols include monitoring (regular weights, side effect tracking, lab follow-up) so the protocol can be adjusted if the dose is producing nothing.
Side effects on microdoses
Most patients report that microdoses produce milder gastrointestinal side effects than standard 2.5 mg dosing. Nausea is typically less intense, vomiting is less common, and constipation may be modest rather than significant.
The trade-off: appetite suppression and weight loss are also lower at microdoses. A 0.5 mg weekly dose may produce 1 to 3% body weight loss over 12 weeks; the FDA-approved 2.5 mg dose produces about 5 to 7% over the same window in clinical trials (Jastreboff et al., NEJM 2022, titration phase data).
Specific side effect profiles patients report at microdoses:
- Nausea: present in roughly 20-30% of patients at 1 mg vs 30-45% at 2.5 mg (clinical-experience estimate)
- Constipation: less common at microdoses; bowel habits may be only slightly altered
- Reflux: lower frequency at lower doses
- Fatigue: variable, may be unrelated to dose
- Hair shedding: less commonly reported on microdoses (since rapid weight loss correlates with telogen effluvium more than dose itself)
These are general patterns. Individual response varies, and some patients still have significant side effects on microdoses.
Risks and limitations of microdosing
Risk 1: Insufficient therapeutic effect. At very low doses, the medication may not produce meaningful weight loss. Patients can stay on a microdose for months and lose nothing. The fix is to titrate up.
Risk 2: Off-label dosing means less safety data. The labeling-recommended doses (2.5 to 15 mg) have substantial randomized safety data. Sub-2.5 mg doses don't. Clinical experience is the main evidence base.
Risk 3: Compounded tirzepatide is the only path to reliable microdosing. Brand-name Mounjaro and Zepbound come in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pre-filled doses. There's no 0.5 mg or 1 mg pen. Patients who want to microdose with a brand-name pen would have to draw a partial dose, which the pen isn't designed for. Compounded tirzepatide drawn from a vial allows precise dose selection.
Risk 4: Self-microdosing without provider direction. Patients sometimes take it upon themselves to cut their dose without telling their provider. The lab and weight monitoring that should accompany a microdose protocol then doesn't happen.
Risk 5: Pharmacy dispensing errors at very low doses. Asking for 0.25 mg or 0.5 mg requires a draw that's at the edge of what an insulin syringe measures accurately. Compounding pharmacies sometimes prefer to dispense at higher concentrations to keep draw volumes practical.
A clinician-directed microdose protocol manages all five of these risks. A self-managed microdose protocol manages none of them well.
FAQ
What is microdose tirzepatide? Microdose tirzepatide is the practice of using doses below the standard FDA-approved 2.5 mg weekly starting dose, typically 0.5 mg to 1.5 mg per week. It's an off-label, clinician-directed protocol used for severe side effects, maintenance after weight goal, or very dose-sensitive patients.
What's the smallest tirzepatide dose I can take? Practically, the smallest reliably-measurable dose on a U-100 insulin syringe is around 0.25 to 0.5 mg, depending on syringe size and vial concentration. Below that, syringe markings become hard to read accurately. Most microdose protocols start at 0.5 mg or 1 mg weekly.
Is microdosing tirzepatide effective for weight loss? Modest weight loss is plausible at microdoses, but the published clinical trial data is on 5 mg, 10 mg, and 15 mg weekly doses. Microdose efficacy is based on clinical experience and pharmacokinetic reasoning, not randomized trials. Individual results vary widely.
Can I microdose with a Mounjaro or Zepbound pen? The brand-name pens are pre-filled at fixed doses (2.5 mg, 5 mg, 7.5 mg, etc.) and aren't designed for partial dosing. Patients who want to microdose typically use compounded tirzepatide drawn from a vial with a U-100 insulin syringe.
How many units is a 1 mg microdose of tirzepatide? At the most common compounded concentration (10 mg/mL), 1 mg = 10 units on a U-100 insulin syringe. At 5 mg/mL it's 20 units; at 20 mg/mL it's 5 units. Always confirm your vial concentration.
Is microdosing tirzepatide safer than the standard dose? Side effects are typically milder at microdoses, but "safer" depends on the comparison. A microdose that's too low may not work, leaving the patient at risk of medication-related side effects without the benefits. A standard dose works but has more side effects. The right answer depends on the patient.
Can I microdose tirzepatide for maintenance after weight loss? Some patients use 1 to 2.5 mg weekly as a maintenance dose after reaching their weight goal. The clinical evidence base is observational rather than randomized. Discuss with your provider, plan monthly weight checks, and have a contingency dose if regain begins.
Will my insurance cover microdose tirzepatide? Insurance coverage of tirzepatide is built around the FDA-approved doses. Microdose protocols using compounded tirzepatide are typically cash-pay since most insurance plans don't cover compounded medications.
How often should I take a microdose? Weekly, like the standard tirzepatide protocol. Tirzepatide's pharmacokinetic half-life of about 5 days makes weekly dosing the appropriate cadence regardless of dose size. Some providers explore biweekly microdosing for very dose-sensitive patients, but this is uncommon.
Can I switch from a microdose back to the standard dose? Yes, with the same care you'd use during a normal titration. Move up incrementally (e.g., 1 mg to 1.5 mg to 2 mg to 2.5 mg) over 2 to 4 weeks per step, watching for side effects.
Is microdosing different for tirzepatide vs semaglutide? The principles are similar but doses differ. Standard semaglutide titration starts at 0.25 mg; microdoses might be 0.1 mg or 0.15 mg. Tirzepatide standard titration starts at 2.5 mg; microdoses are 0.5 mg to 2 mg.
Can I microdose tirzepatide for diabetes prevention without a diabetes diagnosis? Tirzepatide isn't FDA-approved for diabetes prevention. Off-label use for prevention is a clinical judgment call by the prescribing provider, typically reserved for patients with prediabetes and significant cardiometabolic risk. Discuss the off-label nature with your clinician.
Sources
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Frias JP, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight regain (STEP 4). JAMA. 2021;325(14):1414-1425.
- Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. Indianapolis, IN; revised 2024.
- Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. Indianapolis, IN; revised 2024.
- Min T, et al. Pharmacokinetics and pharmacodynamics of tirzepatide. Clin Pharmacokinet. 2022;61(11):1493-1502.
- U.S. Pharmacopeia. USP General Chapter <797>: Pharmaceutical Compounding, Sterile Preparations. USP; 2023 revision.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Footer disclaimers (all 4 verbatim)
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly. Brand names are referenced for educational comparison only.